Keyword: Foresite Capital Management
Foresite Capital will focus on backing companies that use data science and machine learning.
The $58 million financing round represents biopharma industry's growing interest in genomics data.
The series B round equips the team that led BioVex to a $1 billion buyout by Amgen to take another crack at developing a cancer-fighting virus.
The series B equips the biotech to take its lead treatment for multidrug-resistant Gram‐negative infections through clinical trials.